Prostate Cancer International is
for 2011 by Great NonProfits
According to a media release from the Mayo Clinic earlier today, “Alterations to the ‘on-off’ switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.”
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, DNA, expression, gene, methylation, test | 2 Comments »
According to an article in the Boston Globe this morning, we are (supposedly and finally) going to get the study needed to try to demonstrate whether there is a real clinical benefit to proton beam radiation therapy as compared to modern, intensity-modulated radiation therapy in men with localized prostate cancer!
Filed under: Management, Treatment | Tagged: IMRT, PBRT, photon, proton, radiation therapy | 2 Comments »
Here is a link to a recent 20-minute video-discussion on the Medscape web site between an number of European experts on evolutions in the management of castration-resistant (and earlier forms of) prostate cancer.
Filed under: Management, Treatment | Tagged: advanced, castration-resistant, mCRPC, review, video | Leave a Comment »
According to a media release issued today by the National Institute for Clinical Excellence (NICE) in the UK, the institute’s advisory board will not recommend “routine” use of cabazitaxel for the treatment of metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, NICE, UK | 1 Comment »
Malecare has just issued an updated version of its free book on recurrent and advanced prostate cancer. Many people have gained great benefit from the first edition of this book, and we are sure that the new version is equally useful.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: advanced, book, Malecare, recurrent | 2 Comments »
An article acessible for free on the Medscape web site offers an interesting summary of the state of research into the quality of outcomes during and after radical prostatectomy for the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: outcomes, radical prostatectomy, research, surgery | 8 Comments »
According to an article in the online issue of Oncology Business Review (see page 12 of OBR Green), the full results of the clinical trial of abiraterone acetate + prednisone vs. placebo + prednisone in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer (mCRPC) will — as previously suggested — be presented at the upcoming annual [...]
Filed under: Drugs in development, Management, Treatment | 3 Comments »
For those who are interested in seeing a 30-minute video of a presentation and discussion about the development of new drugs like abiraterone, MDV3100, TAK-700 (orteronel), and others, just click here. This video comes from a continuing medical education activity presented in association with the Genitourinary Cancers symposium in San Francisco back in February.
Filed under: Drugs in development, Management | 2 Comments »
We have now been able to track down a link to detailed information about the article by Yu et al. referred to in yesterday’s commentary under the same heading.
Filed under: Diagnosis, Management, Risk | Tagged: aggressive, CNV, copy number variation, progression, risk | 2 Comments »
The abstracts of papers to be presented at the annual meeting of the American Urological Association are now available for scrutiny on-line — including by those who are not attending the meeting. Over the next week of so, The “New” Prostate Cancer InfoLink plans to read through these abstracts and comment on the ones that [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: category, Diagnosis, outcome, risk | 8 Comments »
An article just published in Cancer Research this week suggests that adding the investigational agent enzalutamide (MDV3100) to abiraterone acetate and prednisone in men being treated for metastatic, castration-resistant prostate cancer (mCRPC) may be able to further delay disease progression among men showing signs of progression after initial treatment with abiraterone acetate.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, enzalutamide, mCRPC, MDV3100 | 2 Comments »
A somewhat surprising paper from Johns Hopkins appears (unsurprisingly) to confirm what the Kattan pre-treatment nomogram has been telling us for years … that higher Gleason scores, higher PSA levels, higher clinical stage, and a higher proportion of biopsy cores being positive for prostate cancer are predictive of higher risk for post-surgical recurrence. metastasis, and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pathology, risk, surgery | 1 Comment »
The April issue of AUA News (a magazine only available to AUA members) includes an interesting article by David Penson, MD, in which he previews a lecture he will be giving at the upcoming annual meeting of the American Urological Association (in Atlanta, later this month).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: baseline, database, localized, outcone, regitry, standardized, trial | 6 Comments »
There has been a lot of media hype in Europe around the re-presentation of the PIVOT data by Dr. Wilt at the annual meeting of the European Association of Urology in Paris last week. And yet every prostate cancer specialist attending that meeting must have already been well aware of these data.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Management, obseration, PIVOT, risk, surgery, surveillance, Treatment | 8 Comments »
In the UK, the National Institute for Clinical Excellence (NICE) has just published guidance on the use of focal forms of high-intensity focused ultrasound (HIFU) for the treatment of (low- and intermediate-risk forms of) localized prostate cancer.
Filed under: Diagnosis, Management, Treatment | Tagged: focal, guidance, HIFU, high-intensity focused ultrasound, NICE | 5 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site